medigraphic.com

2015, Number 4

AMC 2015; 19 (4)

Use of porcine surfactant in preterm newborns with early-onset bronchopneumonia

Morilla GAA, Díaz CE, Fernández LO, Ávila AY, Barrese PY

Language: Spanish
References: 25
Page: 348-356
PDF size: 564.50 Kb.


ABSTRACT

Background: there are disagreements about the use of surfactant in bronchopneumonia in newborns.
Objective: to evaluate the behaviour of newborns with early bronchopneumonia treated with exogenous surfactant.
Methods: an open, multicentric, non-randomized or controlled study was conducted in 39 preterm newborns with early bronchopneumonia treated with exogenous surfactant. The gestation age, the birth weight and the stay time in the neonatal intensive care unit, the relation PaO2/FiO2, the mechanical ventilation time, the complications of ventilatory support and the mortality according to the number of doses of exogenous surfactant and the use of prenatal steroids were studied. The absolute and relative frequencies, the average and the chi-squared test were calculated.
Results: the need of administrating a greater number of doses was associated to a lower relation PaO2/FiO2 (p=0,0103). Adequate values were obtained with the first and the second doses. The use of prenatal steroids was associated to a lesser time with mechanical ventilation (p=0,0474), to greater values of the relation PaO2/FiO2(p=0,0162) and to a lower mortality (p=0,0076). No statistical association was found in the complications related to ventilation.
Conclusions: those patients who required a greater number of doses of surfactant had an unfavorable ventilatory response and a greater mortality. The use of prenatal steroids favoured a better ventilatory response and a lower mortality. The combination of prenatal steroids and exogenous surfactant can be beneficial in preterm newborns with early bronchopneumonia.


REFERENCES

  1. Lima Rogel MV, Lemus Varela ML. Sepsis ne-onatal. En: Sola A, editor. Cuidados Neona-tales .Descubriendo la vida de un recién na-cido enfermo. Buenos Aires: Edimed; 2011. p. 519-35.

  2. Ferrieri P, Wallen LD. Neonatal Bacterial Sep-sis. In: Gleason CA, Devaskar SU, editors. Avery’s diseases of the newborn. Philadelph-ia: Saunders-Elsevier Inc.; 2012. p. 538-50.

  3. Craig Jackson J. Respiratory Distress in the Preterm Infant En: Gleason CA, Devaskar SU, editors. Avery’s diseases of the newborn. Philadelphia: Saunders- Elsevier Inc.; 2012. p. 633- 46.

  4. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Registro de morbili-dad continúa. Servicios cerrados de Neona-tología. 2014. La Habana (Cuba): Oficina Na-cional de Estadísticas del MINSAP; 2015.

  5. Valdés Martín S, Gómez Vasallo A, Báez Mar-tínez JM. Temas de Pediatría. 2 ed. La Ha-bana: Editorial Ciencias Médicas; 2011

  6. Pérez Santana Y, Clemades Méndez A M, Mederos Cabana Y, Navarro Ruíz M, Arbelo Hernández I, Molina Hernández O. Rev Cubana Pediatr [Internet]. 2015[citado 12 Mar 2015];87(1):[aprox. 4 p.]. Disponible en: http://bvs.sld.cu/revistas/ped/vol87_1_15/ped07115.htm

  7. Sarmiento Portal Y, Crespo Campos A, Portal Mi-randa ME, Morales Delgado I, Piloña Ruiz S. Aná-lisis de la morbilidad y mortalidad en recién naci-dos con peso inferior a 1 500 g. Rev Cubana Pe-diatr [Internet]. 2009 [citado 12 Sep 2012];81(4):[aprox 3 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S003475312009000400002&lng=es&nrm=iso

  8. Victoria Picardi M. Relaciones estructura-función en el surfactante pulmonar: efecto de la tempe-ratura y mecanismos de compensación fisiológica [tesis]. Madrid: Universidad Complutense de Ma-drid; 2014.

  9. Sola Visner A. Descubriendo las necesidades del recién nacido con insuficiencia respiratoria. Medi-caciones en insuficiencia respiratoria. En: Sola Visner A, editor. Cuidados Neonatales. Descu-briendo la vida de un recién nacido enfermo. Buenos Aires: Edimed; 2011. p. 1038-55

  10. Blanco Hidalgo O, Lugones Ladrón de Guevara Y, Fernandez Limia O, Faure García R. An update on clinical surfactant preparations and respiratory disease. Biotecnología Aplicada [Internet]. 2012 [cited 2013 Dic 22];29:[aprox. 6 p.]. Disponible en: http://scieloprueba.sld.cu/pdf/bta/v29n2/bta01212.pdf

  11. Blanco Hidalgo O, Riverón Alemán Y, de Armas González E, Sánchez J, Faure García R, Fernán-dez Limia O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respirato-rias. Biotecnología Aplicada [Internet]. 2005 [citado 22 Dic 2013];22(4):[aprox 5 p.]. Disponible en: http://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2005/22/4/BA002204OC279-281.pdf

  12. Blanco Hidalgo O, Lugones Ladrón de Guevara Y, Riverón Alemán Y, Núñez Drake A, Toraño Peraza G, Faure García R. Efecto antibacteriano de Surfacen® y la proteína A del surfactante pulmonar frente a un aislado clínico de Strepto-coccus pneumoniae. Rev Salud Anim [Internet]. 2014 [citado 22 Dic 2013];36(1):[aprox 4 p.]. Disponible en: http://scieloprueba.sld.cu/pdf/rsa/v36n1/rsa08114.pdf

  13. Suresh GK, Soll RF. Pharmacologic Adjuncts II: Exogenous Surfactants. En: Goldsmith J, Karot-kin E, editors. Assisted ventilation of the neo-nate. United States of América: Saunders- Else-vier Inc.; 2011. p. 371- 88.

  14. Lopez E, Gascoin G, Flamant C, Merhi M, Tour-neux P, Baud O. Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?. BMC Pediatrics [Internet]. 2013 [citado 22 Dic 2013];13:[aprox. 5 p.]. Disponible en: http://www.biomedcentral.com/1471-2431/13/165

  15. Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Surfactant for bacterial pneumonia in late pre-term and term infants [citado 2014 diciembre 15] [aprox. 4 p.]. Disponible en: http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=4997&id=CD008155&lang=es&dblang=&lib=COC

  16. Moreno Vázquez O, Lee López M, Domínguez Dieppa F, Pascual López MA, Alonso Abad A, Jiménez Rivero G, Manzanares Tapia D. Estudio de la eficacia del Surfacen en el distress respira-torio del recién nacido. Rev Cubana Pediatr [Internet]. 1999 [citado 12 Ago 2014];71(2):[aprox. 11 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S00347531199900020002

  17. Acosta Díaz R, Arronte Millo J, Cabrera Domín-guez N. Evaluación del Surfacen en el síndrome de dificultad respiratoria del prematuro. Rev Cu-bana Pediatr [Internet]. 2000 Oct-Dic [citado 8 Ago 2011];72(4):[aprox. 4 p.]. Disponible en: http://scielo.sld.cu/pdf/ped/v72n4/ped09400.pdf

  18. Manktelow B, Draper ES, Field C, Field D. Esti-mates of length of neonatal stay for very prema-ture babies in the UK. Arch Dis Child Fetal Neo-natal [Internet]. 2010 [citado 2011 Ago 8];95:[aprox. 6 p.]. Disponible en: http://fn.bmj.com/content/95/4/F288.full.pdf+html

  19. Sánchez Mendiola M, Martínez Natera O, Herrera Maldonado N, Ortega Arroyo J. Estudio controla-do del tratamiento de la enfermedad de mem-brana hialina del recién nacido pretérmino con surfactante pulmonar exógeno (porcino vs. bo-vino). Gac Méd Méx [Internet]. 2005 [citado 12 Sep 2014];141(4):[aprox. 4 p.]. Disponible en: http://www.scielo.org.mx/scielo.php?pid=S001638132005000400003&script=sci_arttext&tlng=pt

  20. Jobe A. Surfactant: The Basis for Clinical Treat-ment Strategies. In: Bancalari E, editor. The newborn lung. Neonatology question and contro-versies. New York: Saundier- Elsevier; 2010. p. 73-98.

  21. Beken S, Turkyılmaz C, Koc E, Hirfanoglu IM, Altuntas N. The Effects of Surfactant on Oxygen-ation in Term Infants with Respiratory Failure. Iranian J Pediatr [Internet]. 2013 [citado 12 Sep 2014];23(4):[aprox. 3 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883380/

  22. Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Multiple versus single doses of exogenous surfactant for the prevention or treat-ment of neonatal respiratory distress syn-drome [citado 2014 enero 18] [aprox. 3 p.]. Disponible en: http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=4997&id=CD008155&lang=es&dblang=&lib=

  23. Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Antenatal corticosteroids for acceler-ating fetal lung maturation for women at risk of preterm birth. [citado 2010 abril 30] [aprox. 3 p.]. Disponible en:http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=2643&id=CD004454&lang=es&dblang=&lib=COC

  24. Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Repeat doses of prenatal corticoster-oids for women at risk of preterm birth for improving neonatal health outcomes. [citado 2014 agosto 12] [aprox. 3 p.]. Disponible en://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=2231&id=CD 003935&lang=es&dblang=&lib=COC

  25. Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn JE. Antenatal steroids in preterm labour for the prevention of neonatal deaths due to compli-cations of preterm birth. Int J Epidemiol [Internet]. 2010 [cited 2013 Jul 1];39:[aprox 11 p.]. Disponible en: http://ije.oxfordjournals.org/content/39/suppl_1/i122.full.pdf+html




2020     |     www.medigraphic.com